ArticleOncoTargets and therapy2016
Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Efficacy and safety of apatinib in advanced refractory soft tissue sarcoma and association with histologic subtypes: a multicenter retrospective study.Annals of translational medicine · 2022Article
- Effective Treatment of Low-Grade Myofibroblastic Sarcoma with Apatinib: A Case Report and Literature Review.Pharmacogenomics and personalized medicine · 2022Article
- Article
- The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution.Cancer management and research · 2019Article
- Article
- Apatinib as targeted therapy for sarcoma.Oncotarget · 2018Review
- Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.Cancer biology & therapy · 2018Observational
- The efficacy and safety of apatinib in Ewing's sarcoma: a retrospective analysis in one institution.Cancer management and research · 2018Article
- Article
- Successful treatment of advanced pancreatic liposarcoma with apatinib: A case report and literature review.Cancer biology & therapy · 2017Review
- Apatinib inhibits VEGFR-2 and angiogenesis in anOncotarget · 2017Article
- Advanced alveolar soft part sarcoma responds to apatinib.Oncotarget · 2017Article
- Article
- Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.Oncotarget · 2017Review
- Article
- Successful treatment of angiosarcoma of the scalp with apatinib: a case report.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma in late adult life. Unfortunately, advanced MFH has a poor prognosis due to a lack of effective drugs. We present here a case of advanced MFH with partial response to apatinib, a new potent oral small-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2). To the best of our knowledge, this is the first case report using apatinib for MFH. Quantitative polymerase chain reaction analysis revealed high expression of VEGFR-2 mRNA, suggesting that apatinib leads to clinical response by inhibiting VEGFR-2 tyrosine kinase activity and the crucial role of VEGFR-2 for MFH. Apatinib could be a new option for the treatment of MFH. Further studies are needed to optimize the treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.